Dolutegravir is used to treat HIV-1 in adults and adolescents as part of combination therapy. It helps reduce the viral load to undetectable levels, improve immune function, lower the risk of HIV-related complications, and reduce transmission when taken consistently.

Dolutegravir is an integrase inhibitor that blocks the HIV integrase enzyme, preventing viral DNA from attaching to human DNA. This stops the virus from replicating, lowers viral load, and helps control HIV infection.

Dolutegravir is taken orally as a tablet, usually once daily, with or without food.

Dolutegravir is generally well tolerated, but may cause headache, nausea, diarrhea, fatigue, insomnia, dizziness, or mood changes. Less common effects include weight gain and increased liver enzymes, especially in hepatitis co-infection. Rare serious risks include liver toxicity, hypersensitivity, and IRIS. Patients should report any persistent or unusual symptoms.

Dolutegravir should not be used in people allergic to it or with dofetilide due to serious interactions. Caution is required in liver disease, especially hepatitis B or C. Use in early pregnancy should be evaluated carefully. Side effects like insomnia or mood changes may occur, and consistent use is important to prevent resistance.

Dolutegravir is a highly effective, well-tolerated HIV-1 treatment with once-daily dosing and strong resistance protection. When taken consistently with other antiretrovirals, it supports viral suppression, improves immune health, and lowers transmission risk. With proper monitoring and adherence, it remains a key long-term HIV therapy.

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the HIV integrase enzyme, preventing the integration of viral DNA into the host genome. This step is crucial for viral replication, and its inhibition helps lower the viral load in the body.

Yes. Dolutegravir is effective in both treatment-naïve and treatment-experienced individuals, including some patients who have previously used other integrase inhibitors. However, resistance testing is recommended before initiating therapy in heavily treated individuals.

While Dolutegravir is generally considered safe, early studies raised concerns about a potential risk of neural tube defects when taken during the first trimester. Current guidelines support its use during pregnancy with appropriate counseling and monitoring, especially as newer data suggest the risk is low.

Yes. Dolutegravir should not be used with dofetilide due to life-threatening interactions. It can also interact with antacids and supplements containing magnesium, calcium, or iron, which may reduce its absorption. These should be taken separately or with food to minimize interaction.

Dolutegravir is approved for use in children as young as 4 weeks old and weighing at least 3 kg (in the U.S.), and from age 6 and up in the European Union. Its once-daily dosing and strong efficacy make it an important option in pediatric HIV management.

Weight gain has been observed in some individuals taking Dolutegravir, particularly when combined with tenofovir alafenamide. The cause is not fully understood, and while not harmful in most cases, it should be monitored as part of overall health management.

Liver function tests are recommended, especially for patients with hepatitis B or C co-infection. Renal function may also be monitored depending on the full treatment regimen. Mood changes and sleep disturbances should be reported to a healthcare provider.